Abstract 28P
Background
With the advent of taxanes and targeted agents in neoadjuvant chemotherapy (NACT) for breast cancer, the rates of pathologic complete response (pCR) have been steadily increasing. One of the roles of surgery in these women is to serve the purpose of a biopsy to confirm or negate a pCR.
Methods
We conducted a prospective validation study. Women who had undergone a titanium clip placement followed by neoadjuvant chemotherapy (NACT), and achieved a complete/near complete clinical and radiological response were included. Eligible women underwent an MRI of the breast followed by a US guided core biopsy (CNB) of the tumour bed. The CNB was compared with the final histopathology report after definitive surgery.
Results
65 patients were recruited in this study, of whom 75% had T1/2 tumours and 39 women had hormone negative tumours. The overall rate of pCR in the breast (BrpCR) was 42%. Among women with BrpCR, only one patient had residual disease in the axilla (macrometastasis). The mean number of CNB of the tumour bed after NACT was 4. The accuracy of CNB in predicting BrpCR was 69%, with a false negative rate (FNR) of 14.8%. In a pre-planned sub-group analysis of hormone negative tumours, the FNR was 9.5%. No untoward side effects were observed in any of the patients.
Conclusions
Ultrasound guided CNB of the tumor bed was useful in predicting BrpCR, especially in hormone negative tumours, with an FNR of 9.5%. Increasing the number of cores in the biopsy or changing the imaging modality could help in improving the accuracy of this method.
Clinical trial identification
CTRI/2018/01/011122.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Hyderabad Cancer Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
185P - Evaluation of the effect of cholesorption on the concentration of TNF-α in the serum of the blood in tumours of the biliopancreatoduodenal zone
Presenter: Marufjon Salokhiddinov
Session: Poster display session
Resources:
Abstract
186P - Efficacy and safety of sorafenib following hepatic resection in patients with hepatocellular carcinoma: A meta-analysis
Presenter: Yang Yuan
Session: Poster display session
Resources:
Abstract
187P - Correlation between spleenic dose and grade of hematological toxicity in chemoradiation of stomach
Presenter: Umesh Velu
Session: Poster display session
Resources:
Abstract
188P - Survival and prognostic factors in cholangiocarcinoma: A single-center experience
Presenter: Sonngwit Payapwattanawong
Session: Poster display session
Resources:
Abstract
189P - Stereotactic body radiotherapy in primary hepatocellular carcinoma and oligometastatis to liver: A single Institution experience
Presenter: Sayan Paul
Session: Poster display session
Resources:
Abstract
190P - Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
Presenter: Yusuke Nagata
Session: Poster display session
Resources:
Abstract
191P - Assessment of efficacy and safety of sorafenib versus no treatment in Egyptian hepatocellular carcinoma patients
Presenter: Noha El Baghdady
Session: Poster display session
Resources:
Abstract
192P - Clinical importance of the determination of interleukin-6 in bile and blood in tumours of biliopancreatoduodenal zone
Presenter: Marufjon Salokhiddinov
Session: Poster display session
Resources:
Abstract
193P - Metastatic carcinoma gall bladder: A clinicoepidemiological profile of Indian patients
Presenter: Anvesh Rathore
Session: Poster display session
Resources:
Abstract
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract